Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-22T18:46:27.840Z Has data issue: false hasContentIssue false
  • English
  • Français

Challenges of Applying the SHEA/HICPAC Metrics for Multidrug-Resistant Organisms to a Real-World Setting

Part of: BARRY FARR AWARD RECIPIENTS

Published online by Cambridge University Press:  02 January 2015

E. Yoko Furuya ,
Elaine Larson ,
Timothy Landers ,
Haomiao Jia ,
Barbara Ross  and
Maryam Behta
E. Yoko Furuya*
Affiliation:
Division of Infectious Diseases, Columbia University College of Physicians and Surgeons, New York, New York
Elaine Larson
Affiliation:
School of Nursing, Mailman School of Public Health, Columbia University, New York, New York
Timothy Landers
Affiliation:
College of Nursing, The Ohio State University, Columbus, Ohio
Haomiao Jia
Affiliation:
School of Nursing, Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York
Barbara Ross
Affiliation:
Department of Infection Prevention and Control, New York-Presbyterian Hospital, New York, New York
Maryam Behta
Affiliation:
Department of Information Services, Business Solutions Group, New York-Presbyterian Hospital, New York, New York
*
Division of Infectious Diseases, Columbia University College of Physicians and Surgeons, 622 West 168th Street, PH-8W No. 876, New York, NY 10032 ([email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective.

To test in a real-world setting the recommendations for measuring infection with multidrug-resistant organisms (MDRO) from the Society for Healthcare Epidemiology of America (SHEA) and the Centers for Disease Control and Prevention's Healthcare Infection Control Practices Advisory Committee (HICPAC).

Methods.

Using data from 3 hospital settings within a healthcare network, we applied the SHEA/HICPAC recommendations to measure methicillin-resistant Staphylococcus aureus (MRSA) infection and colonization. Data were obtained from the hospitals' electronic surveillance system and were supplemented by manual medical record review as necessary. Additionally, we tested (1) different definitions for nosocomial incidence, (2) the effect of excluding patients not at risk from the denominator for hospital-onset incidence, and (3) the appropriate time period to use when including or excluding patients with a prior history of MRSA infection or colonization from nosocomial rates. Negative binomial regression models were used to test for differences between rate definitions. A rating scale was created for each metric, assessing the extent to which manual or electronic data elements were required.

Results.

There was no statistically significant difference between using 72 hours or 3 calendar days as the cutoff to define hospital-onset incidence. Excluding patients not at risk from the denominator when calculating hospital-onset incidence led to statistically significant increases in rates. When excluding patients with a prior history of MRSA infection or colonization from nosocomial incidence rates, rates were similar regardless of whether we looked at 1, 2, or 3 years' worth of prior data.

Conclusions.

The SHEA/HICPAC MDRO metrics are useful but can be challenging to implement. We include in our description of the data sources and processes required to calculate these metrics information that may simplify the process for institutions.

Type
Original Article
Information
Infection Control & Hospital Epidemiology , Volume 32 , Issue 4 , April 2011 , pp. 323 - 332
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Cohen, AL, Calfee, D, Fridkin, SK, et al; for the Society for Healthcare Epidemiology of America and the Healthcare Infection Control Practices Advisory Committee. Recommendations for metrics for multidrug-resistant organisms in healthcare settings: SHEA/HICPAC position paper. Infect Control Hosp Epidemiol 2008;29(10):901–913.Google Scholar
2. Siegel, JD, Rhinehart, E, Jackson, M, Chiarello, L. 2007 Guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Confrol 2007;35(10 suppl 2):S65–S164.Google Scholar
3. Sunenshine, RH, Liedtke, LA, Fridkin, SK, Strausbaugh, LJ. Management of inpatients colonized or infected with antimicrobial-resistant bacteria in hospitals in the United States. Infect Control Hosp Epidemiol 2005;26(2):138–143.Google Scholar
4. Veterans Health Administration Directive 2010-006. Methicillin-resistant Staphylococcus aureus (MRSA) prevention initiative. http://wwwl.va.gov/vhapublications/ViewPublication.asp?pub_ID = 2163. Accessed September 16, 2010.Google Scholar
5. Association for Professionals in Infection Control and Epidemiology. MRSA laws and pending legislation—2010 [map], http://www.apic.org/dovmloads/legislation/MRSA_map.gif. Accessed September 16, 2010.Google Scholar
6. Harbarth, S, Fankhauser, C, Schrenzel, J, et al. Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA 2008;299(10):1149–1157.Google Scholar
7. McGinigle, KL, Gourlay, ML, Buchanan, IB. The use of active surveillance cultures in adult intensive care units to reduce methicillin-resistant Staphylococcus aureus-reteted morbidity, mortality, and costs: a systematic review. Clin Infect Dis 2008;46(11):1717–1725.Google Scholar
8. Robicsek, A, Beaumont, JL, Paule, SM, et al. Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. Ann Intern Med 2008;148(6):409–418.Google Scholar